UNICORN CAPITAL PARTNERS
UNICORN CAPITAL PARTNERS is a Seed, Series A, Series B and Series C+ fund in the US, china, asia, europe, africa, russia and emerging-markets investing in Fintech, Healthcare, tmt, real-estate, therapeutics, drug-discovery, gene-therapy, diagnostics-devices, medical-information-technology, residential, commercial and hospitality.
- Stages
- Seed, Series A, Series B, Series C+
- Sectors
- Fintech, Healthcare, tmt, real-estate, therapeutics, drug-discovery, gene-therapy, diagnostics-devices, medical-information-technology, residential, commercial, hospitality
- Invests in
- US-wide, china, asia, europe, africa, russia, emerging-markets
- Founded
- 2015
- Assets under management
- $1.4B
- Website
- unicorn-partners.com
Check size not disclosed
Thesis
The Hong Kong-based entity operates as a fund-of-funds manager focusing on venture capital in China and Asia, targeting early-stage companies in technology, media, telecommunications (TMT), and healthcare, with a preference for seed and early-stage financing rounds. Another entity, a worldwide real estate investment manager, focuses on acquiring and managing prime real estate in key cities across Europe, the USA, and Africa, investing in residential, commercial, and hospitality projects with a transaction volume exceeding €10 billion. A separate venture capital firm based in Moscow, Russia, specializes in Russian companies within the therapeutics, drug discovery, gene therapy, diagnostics devices, and medical information technology sectors, typically investing in Series B and Series C rounds. The firm's overall AUM is reported to be $1.4 billion across 4 funds.
Common questions
Does UNICORN CAPITAL PARTNERS invest at the Seed stage?
Yes. UNICORN CAPITAL PARTNERS lists Seed, Series A, Series B and Series C+ among the stages it invests in.
Where does UNICORN CAPITAL PARTNERS invest?
UNICORN CAPITAL PARTNERS invests in the US, china, asia, europe, africa, russia and emerging-markets.